

Cancer Control Research Training



Community Research Mentors

James Atkins, M.D.

Dr. Atkins is on the CALGB Executive Committee of the Board of Directors as well as the Cancer Control Health Outcomes Committee, a member of the Board of Directors for NSABP Foundation and the Steering Committee for the STAR Trial. He is co-chair of a URCC CCOP protocol assessing informational needs of patients.

Shaker Dakhil, M.D.

Dr. Dakhil is a Clinical Associate Professor at the University of Kansas School of Medicine and a member of the Southwest Oncology Group where his CCOP received last year's annual award for outstanding performance among all CCOP affiliates. Among his 41 publications are: "Association of Immune Parameters with Clinical Outcomes in Stage III Colon Cancer, Results of Southwest Oncology Group Protocol 9009." Cancer Immunology and Immunol Therapy; and "Venlafaxine Alleviates Hot Flashes: An NCCTG Trial," Proceedings of ASCO.

Brian Issell, M.D.

Dr. Issell established the Cancer Prevention and Control Program which was instrumental in the Hawaii Cancer Center receiving National Cancer Institute (NCI) Cancer Center designation. His research interests supported by three NCI and two NIH grants include the use of culturally sensitive, community-based interventions to increase breast and cervical cancer screening in Hawaii's high risk ethnic groups, and the examination of treatment patterns for women diagnosed with breast cancer. He has served on the CAM review committee with Dr. Morrow, directed a cancer control-focused K12 Clinical Oncology Training Award from the NCI and mentored in research projects in cancer prevention and control spanning the disciplines of clinical science, behavioral science and epidemiology and currently is a member of the Internal Advisory Committee and a mentor on a recently-awarded R25 Cancer Control Research Training grant to the University of Hawaii that focuses on minority research issues.

Jeffrey Kirshner, M.D.

Dr. Kirshner has directed the Syracuse CCOP since 1990 and is currently a Clinical Associate Professor at Upstate Medical Center. He has chaired the CCOP membership committee of CALGB and is an investigator for the NSABP. Among his 66 papers and abstracts are: "Phase I

Clinical Study of Fish Oil Fatty Acid Capsules for Patients with Cancer Cachexia, (Cancer and Leukemia Group B Study 9473)”. Clinical Cancer Research.

Marc Conrad, M.D.

Dr. Conrad completed residency and fellowship training at Walter Reed Army Medical Center and commanded a MASH unit in Korea. He is a past Director of the Division of Hematology-Oncology at the University of Alabama at Birmingham and currently directs the Gulf Coast Minority Based CCOP. He is a cancer survivor who served on an NIH hematology study section, chaired the Research Review Committee of the American Red Cross and served as a member of the Manpower Review Committee for NIH Cancer Research. He has been a member of SWOG since 1989 and a Principal Investigator for NSABP since 1991. ‘About half’ of the ‘approximately 80 fellows’ he trained over his career currently have academic affiliations.

P. J. Flynn, M.D.

Dr. Flynn has been a Principal Investigator of the Metro Minnesota CCOP since 1985 and currently is a Clinical Assistant Professor of Medicine at the University of Minnesota and board qualified in internal medicine and oncology and hematology. He is co-chair of two URCC CCOP protocols: “Oral Antibiotic Prophylaxis of Early Infection in Multiple Myeloma.” And “Sandostatin LAR[®] Depot (octreotide acetate) for Prevention of Chemotherapy-Induced Diarrhea in Colorectal Cancer Patients” Among his 32 publications are: “Documented Colorectal Surveillance Guidelines by the American Society of Clinical Oncology,” Journal of Clinical Oncology; “Use of 5-HT₃ Receptor Antagonist to Prevent Nausea and Emesis Caused by Chemotherapy for Patients with Breast Carcinoma in Community Practice Settings,” Cancer.

Philip Kuebler, M.D, Ph.D.

Dr. Kuebler is on the Board of Governors of the Southwest Oncology Group (SWOG) and is the Principal Investigator of the Columbus CCOP. He has been the Principal Investigator of 11 clinical trials from SWOG, the Research Consortium Trials Network and NSABP. He is currently the Principal Investigator of an award for “Breast Health Project” from the Susan G. Komen Breast Cancer Foundation. Among his 25 professional publications are three peer-reviewed reports in Astronomy journals along with: “Evaluation of Gemcitabine in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Investigational New Drugs; and “Influence of the Timing of Surgery in Relation to the Menstrual Cycle on Recurrence and Survival in Breast Cancer.”